Endocrinopathies with use of cancer immunotherapies. (9th October 2017)

• Record Type: Journal Article
• Authors: Villa, Natalie M.; Farahmand, Abtin; Du, Lin; Yeh, Michael W.; Smooke‐Praw, Stephanie; Ribas, Antoni; Chmielowski, Bartosz; Cherry, Grace; Leung, Angela M.
• Is Part Of: Clinical endocrinology. Volume 88:Number 2(2018)
• Page Start: 327
• Page End: 332
• Publication Date: 2017-10-09
• Subjects: hyperthyroidism -- hypopituitarism -- thyroiditis; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.13483
• Languages: English
• ISSNs: 0300-0664

Abstract

Summary: Background: Immunomodulatory therapies, including CTLA‐4 and PD‐1 inhibitors, provide a directed attack against cancer cells by preventing T cell deactivation. However, these drugs also prevent the downregulation of auto‐reactive T cells, resulting in immune‐related adverse events (IRAEs). Reports show a varied incidence of endocrine IRAEs, ranging from 0% to 63%. Objective: To describe the frequency and clinical characteristics of endocrine IRAEs in patients taking cancer immunomodulatory therapies. Design: Retrospective cohort study. Patients: A total of 388 patients aged ≥18 years who were prescribed ipilimumab, nivolumab and/or pembrolizumab between 2009 and 2016 at our institution. Measurements: Biochemical criteria were used to define endocrine IRAEs, including thyroid, pituitary, pancreas and adrenal dysfunction, following use of immunomodulatory therapies. Results: Fifty endocrine IRAEs occurred in our cohort, corresponding to a rate of 12.9%. The most common endocrine IRAEs were thyroid dysfunction (11.1%), with a lower incidence of pituitary dysfunction (1.8% of patients). Conclusions: Over 12% of patients receiving ipilimumab, nivolumab and/or pembrolizumab in our study sample developed an endocrine IRAE. Patients who undergo treatment with immunomodulatory therapies should be monitored for the development of endocrine IRAEs.